Quigley Corporation Launches Redesigned Quigley Pharma Web Site; Web Site Engages Strategic Partners And Stock Holders With View On Holistic Approach To Pharmaceutical Development
DOYLESTOWN, Pa., Aug. 28 /PRNewswire-FirstCall/ -- Quigley Pharma, a wholly-owned subsidiary of The Quigley Corporation , announced today the launch of www.quigleypharma.com. The site aims to inform Quigley Corporation investors of ongoing Research and Development efforts and engage potential strategic pharmaceutical partners by providing information regarding Quigley Pharma's naturally derived pharmaceutical compounds.
"Quigley Pharma is one of the few companies working to create prescription drugs from natural sources," said Guy Quigley, Chief Executive Officer, Quigley Corporation. "The Web site affords visitors, particularly the investment community, insight to our holistic approach and the value we see in these natural sources. It will also provide updates to the ongoing effort to bring our research compounds to market," concluded Mr. Quigley.
Quigley Pharma is developing compounds that address major health issues facing the world today including Diabetic Peripheral Neuropathy, Avian Flu, Systemic Radiation and Cachexia (muscle wasting often associated with cancer and AIDS) among others.
Featuring a new fresh, modern design, the site is divided into three primary categories:
Research and Development -- provides information about the company's most current R&D, Therapeutic areas of interest, Compound Profiles as well as information regarding Research and Development Partners including Quigley Pharma's Scientific Advisory Board. Investor Relations -- provides the financial community and investors with information on The Quigley Corporation which manufactures and markets over-the-counter consumer cold remedy brands; health and wellness supplements. The site will feature SEC filings, financial and stock information, and an opportunity for visitors to sign up to receive company email alerts. News & Media -- to keep media and investors well informed, this section contains current and archived press releases and an opportunity for site visitors to sign up for email updates.
"The site further strengthens our communications efforts and demonstrates our commitment to keeping investors and potential investors informed regarding the efforts of Quigley Pharma," added Mr. Quigley.
The company also plans to update the main corporate site at www.quigleyco.com that will mirror Investor Relations sections in the new Quigley Pharma page in the near future.
About The Quigley Corporation
The Quigley Corporation is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries. Darius International markets health and wellness products through its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD-EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived prescription drugs.
Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.
CONTACT: Media Investor Relations Karen Pineman Carl Hymans G.S. Schwartz & Co. G.S. Schwartz & Co. 212.725.4500 212.725.4500 firstname.lastname@example.org@schwartz.comThe Quigley Corporation
CONTACT: Media: Karen Pineman, email@example.com, or InvestorRelations: Carl Hymans, both of G.S. Schwartz & Co. for The QuigleyCorporation, +1-212-725-4500